Hepatitis B vaccine

US9878035B2 · kind B2 · utility

Assignee

• JIANGSU THERAVAC BIO-PHARMACEUTICAL CO., LTD. · CN

Inventors

• Sean Xiaohan Du · Nanjing, CN
• Jun Ge · Nanjing, CN
• Xiaoqian Zhuang · Nanjing, CN
• Tong Zhou · Overland Park, US
• Jianqiang Li · Nanjing, CN
• Cuiling Song · Nanjing, CN
• Ying Sun · Waltham, US
• Meiju Wang · Nanjing, CN
• Yue Gu · Nanjing, CN
• Honglin Sun · Nanjing, CN
• Zhenxing Xu · Nanjing, CN
• Hongying Huang · Zhejiang, CN
• Xiaoxiao Chen · Nanjing, CN

Key dates

• Filing date: Feb 26, 2014
• Grant date: Jan 30, 2018
• Expiry date: Mar 19, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2730/10171
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a composition comprising: i) HBsAg, a fragment thereof, a variant thereof, or the mixture of at least two of them, ii) HBcAg1-X, a fragment thereof, a variant of the antigen or the antigen fragment, or the mixture of at least two of them, wherein X is an integer of from 149 to 183, iii) CpG-ODN, 21 bases long, which is a phosphorothioate oligonucleotide and includes two or more copies of 5′-NTCGTT-3′ motifs. The use of the composition in the treatment of HBV-infection and HBV-induced diseases, and the therapy methods of HBV-infection and HBV-induced diseases are also disclosed.